Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease

Marcus M. Ilg, Simon J. Stafford, Marta Mateus, Stephen A. Bustin, Michael J. Carpenter, Asif Muneer, Trinity J. Bivalacqua, David J. Ralph, Selim Cellek

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease'. Together they form a unique fingerprint.

Medicine & Life Sciences